Denmark· DK-28101882397
NovoNorm
A repaglinide product containing repaglinid, registered in Denmark by Novo Nordisk A/S. The same ATC class is registered in 19 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Repaglinide is registered in 19 of 19 countries.
Countries holding a registration under ATC A10BX02 (repaglinide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 11 of them publish a price we can compare per daily dose
Repaglinide · ATC A10BX02
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of repaglinide costs, country by country.
Normalised to the WHO defined daily dose (4 mg), the median price runs from $0.30 in France to $1.47 in Switzerland — a ×4.9 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Repaglinide · price per daily dose (4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.47
- IT Italy$0.39
- FR France$0.30
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- REPAGLINID
- Manufacturer
- Novo Nordisk A/S
- Country
- Denmark (DK)
- ATC code
- A10BX02
- ATC class
- Repaglinide
- Defined daily dose
- 4 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28101882397
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
708 interactions on record for repaglinide.
Graded by severity as the source publishes them — 18 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Repaglinide · interactions on record
708 records
- 18 severe
- 502 moderate
- 41 minor
- 145 info
Most severe, free to view
- ClopidogrelB01AC04severe
- GemfibrozilC10AB04severe
- ClotrimazoleA01AB18moderate
- CimetidineA02BA01moderate
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10BX02
Repaglinide, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d870c9dc-78ca-4117-82ff-64d5a92d844e GET /v1/drugs/d870c9dc-78ca-4117-82ff-64d5a92d844e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "tabletter",
"source": "dkma",
"strength": "0,5 mg",
"auth_role": "MOD",
"dk_drugid": "28101882397",
"substance": "REPAGLINID",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "36024"
}See everything about repaglinide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.